# The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

> **NCT06520345** · PHASE3 · RECRUITING · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 520 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** 177Lu-TLX591
- **DRUG:** Enzalutamide
- **DRUG:** Abiraterone
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT06520345
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-26
- **Primary completion:** 2027-12
- **Final completion:** 2030-12
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06520345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06520345, "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06520345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*